InvestorsHub Logo
Followers 48
Posts 9807
Boards Moderated 1
Alias Born 01/31/2008

Re: raja48185 post# 99137

Thursday, 05/23/2019 1:21:11 PM

Thursday, May 23, 2019 1:21:11 PM

Post# of 108192
Yes, the incompetence is throughout ADXS.

Not only a criminally incompetent Chairman of the Board, who hired 4 dog CEOs in a row.

Not only the 4 dog CEOS in a row.

Not only the clueless self-promoting greedy CFO who went to ONCS.

But also the Chief Science Officer, who is clueless on how to structure trials and get them approved promptly.

One example of this incompetence: It is standard procedure to pair trials with genomic testing in cancer studies, as certain therapies may only work for certain people with one type of genetics. ADXS never did this. If they had, maybe the lukewarm results that their vaccines showed would have been stellar in a particular subset of the population. Major screwup by Petit there, but par for the course at non-merit raises ADXS.

Amgen dumps NEO, votes thumbs down on ADXS & ADXS "LM Technology Platform" & buys out Nuevolution

Yes, there you have it. Market validation that part of the ADXS problem is the science is not that good. Money talks. So much for the idea that AMGN was not interested in cancer treatments that was floated around here.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News